Skip to main content

Comment on Withdrawn Non-Binding Offer

HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ: EVO)

Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for EUR11.00 per share in cash.

The Management Board and Supervisory Board of Evotec, together with its advisors, have been in the process of thoroughly assessing the Non-Binding Proposal submitted by Halozyme in a letter dated 13 November 2024, in which it expressed an interest in a combination of Halozyme with Evotec.

The Management Board and Supervisory Board continue to have strong conviction in the Company's standalone strategy, which is expected to accelerate growth, strengthen the long-term profitability of the Company and deliver significant value to shareholders.

- End of the ad hoc release -

Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com

SOURCE: Evotec SE



View the original press release on accesswire.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.42
+5.94 (2.74%)
AAPL  264.12
+1.88 (0.72%)
AMD  238.76
-1.80 (-0.75%)
BAC  51.95
-0.09 (-0.18%)
GOOG  248.08
-8.94 (-3.48%)
META  731.32
-0.85 (-0.12%)
MSFT  515.98
-0.81 (-0.16%)
NVDA  182.21
-0.43 (-0.24%)
ORCL  280.00
+2.82 (1.02%)
TSLA  447.65
+0.22 (0.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.